scholarly journals Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience

2020 ◽  
Vol 25 (11) ◽  
Author(s):  
Sandy S. Bohan ◽  
Jason K. Sicklick ◽  
Shumei Kato ◽  
Ryosuke Okamura ◽  
Vincent A. Miller ◽  
...  
Keyword(s):  
Precision Oncology ◽  
Trial Analysis ◽  
Oncology Trial

Abstract 821: Comprehensive genomic analysis of rare cancers: Results of the MASTER precision oncology trial of the German Cancer Consortium

2020 ◽  
Author(s):  
Peter Horak ◽  
Christoph Heining ◽  
Andreas Mock ◽  
Simon Kreutzfeldt ◽  
Andreas Lassmann ◽  
...  
Keyword(s):  
Genomic Analysis ◽  
Precision Oncology ◽  
Rare Cancers ◽  
Oncology Trial

scholarly journals The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies

Cancer Cell ◽  
2021 ◽  
Vol 39 (1) ◽  
pp. 22-24
Author(s):  
Yonina R. Murciano-Goroff ◽  
Alexander Drilon ◽  
Zsofia K. Stadler
Keyword(s):  
Precision Oncology ◽  
Oncology Trial

Research round-up: Precision oncology

Nature ◽  
2020 ◽  
Vol 585 (7826) ◽  
pp. S2-S3
Author(s):  
Laura Vargas-Parada
Keyword(s):  
Precision Oncology

Avenues to Precision Oncology

2020 ◽  
pp. 36-45
Author(s):  
Alexander Meisel
Keyword(s):  
Precision Medicine ◽  
Trial Design ◽  
Ad Hoc ◽  
Molecular Targets ◽  
Clinical Trial Design ◽  
Predictive Biomarkers ◽  
Precision Oncology ◽  
Companion Diagnostics ◽  
Bona Fide ◽  
The One

Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with ad hoc guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as bona fide targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design.

scholarly journals Best Paper Selection

2018 ◽  
Vol 27 (01) ◽  
pp. 226-226
Keyword(s):  
Prostate Cancer ◽  
Knowledge Base ◽  
Prediction Models ◽  
Precision Oncology ◽  
Castration Resistant Prostate Cancer ◽  
Short Term ◽  
Castration Resistant

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017 Jul;2017 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28890946/ Newton Y, Novak AM, Swatloski T, McColl DC, Chopra S, Graim K, Weinstein AS, Baertsch R, Salama SR, Ellrott K, Chopra M, Goldstein TC, Haussler D, Morozova O, Stuart JM. TumorMap: exploring the molecular similarities of cancer samples in an interactive portal. Cancer Res 2017 Nov 1;77(21):e111-e114 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29092953/ Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Winner KK, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC, and Prostate Cancer DREAM Challenge Community. A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer. JCO Clin Cancer Inform 2017 Aug 4;(1):1-15 http://ascopubs.org/doi/abs/10.1200/CCI.17.00018

Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma

2020 ◽  
Author(s):  
Sara Akhavanfard ◽  
Lamis Yehia ◽  
Roshan Padmanabhan ◽  
Jordan P Reynolds ◽  
Ying Ni ◽  
...  
Keyword(s):  
Young Adults ◽  
Adrenocortical Carcinoma ◽  
Kinase Inhibitor ◽  
Mapk Pathway ◽  
Adolescents And Young Adults ◽  
Control Group ◽  
Precision Oncology ◽  
Sequencing Data ◽  
Germline Variants ◽  
Mutant Cells

Abstract Adrenocortical Carcinoma (ACC) is a rare endocrine tumor with poor overall prognosis and 1.5-fold overrepresentation in females. In children, ACC is associated with inherited cancer syndromes with 50–80% of childhood-ACC associated with TP53 germline variants. ACC in adolescents and young adults (AYA) is rarely due to germline TP53, IGF2, PRKAR1A and MEN1 variants. We analyzed exome sequencing data from 21 children (<15y), 32 AYA (15-39y), and 60 adults (>39y) with ACC, and retained all pathogenic, likely pathogenic, and highly prioritized variants of uncertain significance. We engineered a stable lentiviral-mutant ACC cell line, harboring an EGFR variant (p.Asp1080Asn) from a 21-year-old female without germline-TP53-variant and with aggressive ACC. We found that 4.8% of the children (P = 0.004) and 6.2% of AYA (P < 0.0001), all-female participants, harbored germline EGFR variants, compared to only 0.3% of the control group. Expanding our analysis to the RTK-RAS-MAPK pathway, we found that the RTK genes have the highest number of highly prioritized germline variants in these individuals amongst all three arms of this pathway. We showed EGFR mutant cells migrate faster and are characterized by a stem-like phenotype compared to wild type cells. While EGFR inhibitors did not affect the stemness of mutant cells, Sunitinib, a multireceptor tyrosine kinase inhibitor, significantly reduced their stem-like behavior. Our data suggest that EGFR could be a novel underlying germline predisposition factor for ACC, especially in the Childhood-AYA (C-AYA) population. Further clinical validation can improve precision oncology management of this disease, which is known to have limited therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document